Clinical trials: ICU-acquired Muscle Weakness
Muscle Weakness, Sepsis
Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
ICU acquired muscle weakness is a significant problem in patients recovering from critical illness. This trial will evaluate the safety and efficacy of a drug in improving muscle weakness in critically ill patients.
- Trial name
- EMILI (NCT02523690)
- Testing
- Lorcaserin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Muscle Atrophy, Muscle Weakness
Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome
Post-intensive care syndrome (PICS) encompasses persistent physical, cognitive, and psychiatric symptoms following ICU discharge, commonly triggered by serious conditions such as respiratory failure, sepsis, and mechanical…
- Conditions
- Muscle Atrophy, Muscle Weakness, Blood Flow
- Trial name
- NCT06238609
- Testing
- Intervention Group, Control Group
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bijan Najafi, PhD
ICU Acquired Weakness
Diagnosing Intensive Care Unit (ICU) Acquired Weakness
The goal of this study is to develop a non-invasive test to diagnose intensive care unit (ICU) acquired weakness that can be administered to both responsive and non-responsive patients.
- Trial name
- NCT04166630
- Testing
- Clinical Electrical Stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
ICU Acquired Weakness
Evaluation of FDY-5301 in Major Trauma Patients in ICU
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)
- Trial name
- NCT04430283
- Testing
- FDY-5301
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Faraday Pharmaceuticals, Inc.